Q4 EPS Estimates for Globus Medical Lifted by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Roth Capital lifted their Q4 2025 earnings per share estimates for shares of Globus Medical in a research note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now anticipates that the medical device company will post earnings per share of $0.96 for the quarter, up from their previous estimate of $0.91. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share.

Globus Medical (NYSE:GMED) last issued its earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.18. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The company had revenue of $625.71 million during the quarter, compared to the consensus estimate of $604.69 million. During the same quarter in the prior year, the business earned $0.57 earnings per share. The company’s revenue was up 63.1% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company lifted their price objective on shares of Globus Medical from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Royal Bank of Canada raised their price target on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th. Bank of America upped their price objective on shares of Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Globus Medical from $85.00 to $92.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Stifel Nicolaus increased their price target on Globus Medical from $80.00 to $92.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $94.55.

Globus Medical Stock Up 0.8 %

Shares of GMED opened at $82.63 on Thursday. The firm has a market cap of $11.25 billion, a price-to-earnings ratio of 123.33, a PEG ratio of 1.99 and a beta of 1.19. The business’s 50 day moving average is $80.02 and its two-hundred day moving average is $73.34. Globus Medical has a 52-week low of $49.33 and a 52-week high of $87.22.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total value of $2,251,200.00. Following the transaction, the director now owns 536,275 shares of the company’s stock, valued at approximately $40,242,076. This trade represents a 5.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel T. Scavilla sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. Insiders have sold 97,500 shares of company stock valued at $7,674,950 in the last 90 days. 18.54% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in GMED. Select Equity Group L.P. acquired a new position in shares of Globus Medical in the second quarter valued at approximately $91,711,000. Millennium Management LLC grew its holdings in shares of Globus Medical by 1,171.5% in the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after acquiring an additional 1,256,570 shares in the last quarter. ArrowMark Colorado Holdings LLC acquired a new stake in shares of Globus Medical in the third quarter valued at about $43,947,000. Lord Abbett & CO. LLC acquired a new position in Globus Medical during the third quarter valued at approximately $37,948,000. Finally, Parsifal Capital Management LP grew its stake in Globus Medical by 50.5% in the third quarter. Parsifal Capital Management LP now owns 1,350,553 shares of the medical device company’s stock valued at $96,619,000 after purchasing an additional 453,053 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.